The Cancer-focused Genetic Testing Service Market Size is valued at USD 7.82 billion in 2023 and is predicted to reach USD 14.41 billion by the year 2031 at an 8.2% CAGR during the forecast period for 2024-2031.
Genetic testing services that specifically target cancer are an essential part of contemporary oncology, providing substantial advantages in evaluating risk, preventing the disease, and tailoring treatment to individual patients. Through comprehending genetic predispositions, individuals and healthcare practitioners can make well-informed judgments that enhance outcomes and potentially preserve lives.
The increasing prevalence of cancer worldwide is fueling the need for specialized genetic testing services tailored to cancer detection. Prompt detection and personalized therapy are crucial as the prevalence of cancer increases. Genetic testing services have the ability to identify gene mutations that drive the likelihood of developing cancer, allowing for focused treatment and preventative strategies. These services are also more precise and efficient due to the utilization of advanced genetic testing technologies such as next-generation sequencing (NGS). Next-generation sequencing (NGS) rapidly and comprehensively examines many genes, unveiling an individual's genetic makeup and susceptibility to cancer. This technique has facilitated cost reduction and simplification of genetic testing, hence fostering the growth of the sector.
The cancer-specific genetic testing business faces obstacles due to regulatory and ethical concerns, despite its increasing potential. The development and adoption of novel diagnostic technologies might be hindered by restrictions on patient privacy and the exploitation of genetic data. Issues such as hereditary discrimination and the psychological impact of test results add complexity to the situation. Specialized expertise is required for the interpretation of genetic data, so skilled specialists are necessary. The limited availability of these experts might impede the collaboration of genetic testing into clinical practice.
The Cancer-focused Genetic Testing Service market is segmented on the basis of Test Type, Cancer Type, and Service Provider. Based on Test Type segment, the market is divided into Chromosome Testing, DNA Testing, Direct DNA Testing, Indirect DNA Testing, and Biochemical Genetic Testing. By Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Bladder Cancer, Colorectal Cancer, Kidney Cancer, and Others. By service providers, the market is segmented into hospitals, speciality clinics, diagnostic laboratories, and specialized cancer institutes.
The Breast Cancer sub-segment is expected to hold a major share in the global Cancer-focused Genetic Testing Service market in 2023. Breast cancer, a widespread kind of cancer that affects women worldwide, often does not exhibit clear signs in its first stages. The proliferation of private diagnostic centres for breast cancers worldwide may be ascribed to escalating demand for diagnostic imaging operations and the increasing burden on public hospitals, which often have restricted access to imaging modalities. In response to this prevailing pattern, FUJIFILM Corporation developed NURA, a dedicated medical screening facility with a specific emphasis on cancer screening, located in Bangalore, India. This facility is a partnership between FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty's Healthcare (DKH). FUJIFILM DKH LLP is a collaborative partnership between FUJIFILM and Dr. Kutty's Healthcare, a healthcare provider that manages hospitals and screening facilities across India and the Middle East.
Conversely, the diagnostic laboratory category is seeing the most rapid growth among end users in the worldwide genetic testing market. Genetic testing firms are forming partnerships and collaborations with digital labs, resulting in a rapid increase in their growth rate. Thermo Fisher Scientific has facilitated genetic research in labs by offering tools such as NGS (Next-Generation Sequencing) and quantitative PCR. The use of these emerging technologies will facilitate the detection and analysis of genetic testing, hence stimulating market growth throughout the projected timeframe.
North America leads the way in market innovation due to its robust healthcare infrastructure, rapid technology advancements, and elevated prevalence of cancer. Prominent industry leaders emphasize the advancement of genetic testing capabilities to provide complete solutions for tailored cancer treatment and prevention.The market is also propelled by government initiatives targeted at fostering accessible healthcare and advancements in genetic research and technology. Leading companies in these fields use artificial intelligence and big data analytics to improve the accuracy and efficiency of genetic testing, hence fueling their rapid expansion in the market. Moreover, The Asia-Pacific region is at the forefront of the market for cancer-focused genetic testing services. This phenomenon may be attributed to the fast development of the healthcare sector and the growing incidence of cancer, both of which are fueled by significant investments. These nations benefit from the increase in healthcare expenditure, the expansion of the middle-class population, and the increasing recognition of the benefits of genetic testing for cancer therapy.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 7.82 Bn |
|
Revenue Forecast In 2031 |
USD 14.41 Bn |
|
Growth Rate CAGR |
CAGR of 8.2% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Test Type, Cancer Type And Service Provider |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Cleveland Clinic, Fortis Healthcare, KIMS Hospitals, Rush University Medical Center, The Johns Hopkins Hospital, Bridgeport Hospital, Greenwich Hospital, Lawrence Memorial Hospital, Westerly Hospital, Yale New Haven Hospital, and Northeast Medical Group. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer-Focused Genetic Testing Service Market Snapshot
Chapter 4. Global Cancer-Focused Genetic Testing Service Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Test Type Estimates & Trend Analysis
5.1. By Test Type & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Test Type:
5.2.1. Chromosome
5.2.2. DNA
5.2.3. Direct DNA Testing
5.2.4. Indirect DNA Testing
5.2.5. Biochemical
Chapter 6. Market Segmentation 2: By Cancer Type Estimates & Trend Analysis
6.1. By Cancer Type & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Cancer Type:
6.2.1. Breast Cancer
6.2.2. Colorectal Cancer
6.2.3. Lung Cancer
6.2.4. Bladder Cancer
6.2.5. Kidney Cancer
6.2.6. Other Cancer Types
Chapter 7. Market Segmentation 3: By Service Provider Estimates & Trend Analysis
7.1. By Service Provider & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Service Provider:
7.2.1. Hospitals
7.2.2. Specialty Clinics
7.2.3. Diagnostic Laboratories
7.2.4. Specialized Cancer Institutes
Chapter 8. Cancer-Focused Genetic Testing Service Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
8.1.2. North America Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.1.3. North America Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Service Provider, 2024-2031
8.1.4. North America Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
8.2.2. Europe Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.2.3. Europe Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Service Provider, 2024-2031
8.2.4. Europe Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
8.3.2. Asia Pacific Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.3.3. Asia Pacific Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Service Provider, 2024-2031
8.3.4. Asia Pacific Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Asia Pacific Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
8.4.2. Latin America Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.4.3. Latin America Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Service Provider, 2024-2031
8.4.4. Latin America Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
8.5.2. Middle East & Africa Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.5.3. Middle East & Africa Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by Service Provider, 2024-2031
8.5.4. Middle East & Africa Cancer-Focused Genetic Testing Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Cleveland Clinic
9.2.2. Fortis Healthcare
9.2.3. KIMS Hospitals
9.2.4. Rush University Medical Center
9.2.5. The Johns Hopkins Hospital
9.2.6. Bridgeport Hospital
9.2.7. Greenwich Hospital
9.2.8. Lawrence Memorial Hospital
9.2.9. Westerly Hospital
9.2.10. Yale New Haven Hospital
9.2.11. Northeast Medical Group
9.2.12. Other Prominent Players
Cancer-focused Genetic Testing Service Market By Test Type -
Cancer-focused Genetic Testing Service Market By Cancer Type -
Cancer-focused Genetic Testing Service Market By Service Provider-
Cancer-focused Genetic Testing Service Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
